Evidence map›Paper›PMID 10398282›Full record

ArticleThe Prostate1999

Inhibitory effect of zinc on human prostatic carcinoma cell growth.

J Y Liang, Y Y Liu, J Zou, R B Franklin, L C Costello, P Feng

Abstract read
In one paragraph

Article in The Prostate, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers.

0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed
5.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

80 citing papers in PubMed, 255 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Zinc: From Biological Functions to Therapeutic Potential.International journal of molecular sciences · 2023
    Review
  7. Review
  8. Emerging Hallmarks of Metabolic Reprogramming in Prostate Cancer.International journal of molecular sciences · 2023
    Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. The role of nutritional interventions in prostate cancer: A review.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2021
    Review
  15. Article
  16. Zinc: The Wonder Drug for the Treatment of Carcinomas.Acta scientific cancer biology · 2020
    Article
  17. Review
  18. Advances of Zinc Signaling Studies in Prostate Cancer.International journal of molecular sciences · 2020
    Review
  19. Article
  20. Article

20 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

J Y LiangMolecular and Cellular Biology Section, Department of OCBS, University of Maryland Dental School, Baltimore, Maryland 21201, USA.
Y Y Liu
J Zou
R B Franklin
L C Costello
P Feng
University of Maryland, Baltimore · US

Funding

HORMONAL AND ZINC REGULATION OF PROSTATE M-ACONITASER01CA071207 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI COSTELLO, LESLIE C · 1996 to 2004
$986k
PROLACTIN REGULATION OF PROSTATE CITRATE PRODUCTIONR01DK042839 · NIDDK · UNIVERSITY OF MARYLAND BALTIMORE · PI FRANKLIN, RENTY B. · 1992 to 2003
$980k
TESTOSTERONE CONTROL OF PROSTATE CITRATE PRODUCTIONR01DK028015 · NIDDK · UNIVERSITY OF MARYLAND BALTIMORE · PI COSTELLO, LESLIE C · 1986 to 1999
–
TRH AND TRH-RELATED PEPTIDES AND TESTISR29HD030818 · NICHD · UNIVERSITY OF MARYLAND BALTIMORE · PI FENG, PEI · 1995 to 1999
–
NCI NIH HHS R01 CA071207NICHD NIH HHS HD30818NIDDK NIH HHS DK28015NIDDK NIH HHS DK42839NIDDK NIH HHS R01 DK042839
6 · The paper itself

Abstract

backgroundNormal human prostate accumulates the highest levels of zinc of any soft tissue in the body. In contrast, the zinc level in prostate cancer is markedly decreased from the level detected in nonprostate tissues. Despite these relationships, the possible role of zinc in the growth of normal and malignant prostate has not been determined.

methodsGrowth inhibition and various regulatory responses were investigated in two human prostate carcinoma cell lines (LNCaP and PC-3), treated with or without zinc.

resultsIncubation of the prostate carcinoma cell lines with physiological levels of zinc resulted in the marked inhibition of cell growth. A lower 50% inhibition of cell growth (IC50) value for zinc (about 100 ng/ml) was detected in LNCaP cells, which are androgen-responsive, whereas androgen-independent PC-3 cells exhibited a higher IC50 for zinc (about 700 ng/ml). Incubation with 1 microg/ml zinc resulted in maximum inhibition of growth in both cell lines. These inhibitory effects of zinc correlated well with the accumulation of zinc in the cells. Simultaneously, cell flow cytometric analyses revealed a dramatic increase of the cell population in G2/M phase, in both LNCaP (2.3-fold vs. control) and PC-3 (1.9-fold vs. control), and a decreased proportion of cells in S phase (LNCaP, -51.4%; PC-3, -23%), indicating a G2/M phase arrest. The cell growth inhibition and G2/M arrest in these cells were accompanied by an increase in apoptosis, as demonstrated by the characteristic cell morphology and further confirmed by cellular DNA fragmentation. The specificity of zinc-induced apoptosis was identified by ethylenediamine-tetraacetic acid (EDTA)-chelation, which abolished the zinc effect on cellular DNA fragmentation. The zinc-induced G2/M phase arrest and apoptosis were accompanied by increased mRNA levels of p21(Waf1/Cip1/Sdi1) in both LNCaP (p53+/+) and PC-3 (p53-/-) cells.

conclusionsThese results suggest that zinc inhibits human prostatic carcinoma cell growth, possibly due to induction of cell cycle arrest and apoptosis. There now exists strong evidence that the loss of a unique capability to retain high levels of zinc is an important factor in the development and progression of malignant prostate cells.

Indexed as

ApoptosisCell CycleCell DivisionCyclin-Dependent Kinase Inhibitor p21CyclinsDNA FragmentationEnzyme InhibitorsFlow CytometryG2 PhaseGene Expression Regulation, NeoplasticHumansKineticsMaleMitosisProstatic NeoplasmsTranscription, GeneticCDKN1A protein, humanCyclin-Dependent Kinase Inhibitor p21CyclinsEnzyme InhibitorsZinc

Identifiers

PMID10398282
PMCPMC4465333
OpenAlexW1967714958

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.